AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33538686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital continuous positive airway pressure (O‐Two system, O‐Two Medical Technologies Inc.)
Number of subjects: 77
Study 33538686 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy, titrated to the British Thoracic Society's peripheral oxygen saturation targets
Number of subjects: 77
Study 32320846 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based self-management support, including one face-to-face start-up session followed by telephone sessions.
Number of subjects: 4400
Study 32320846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 4400
Study 34967444 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Possible Medication History (BPMH) approach
Number of subjects: 372
Study 34377501 — intervention group
Group type: EXPERIMENTAL
Intervention: Web application (digital tool)
Number of subjects: 77
Study 34377501 — intervention group
Group type: COMPARATOR
Intervention: Paper form (active control)
Number of subjects: 77
Study 34377501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tools (web app and paper form)
Number of subjects: 77
Study 36322558 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation‐based Balance Training (PBT)
Number of subjects: 34
Study 36322558 — intervention group
Group type: COMPARATOR
Intervention: Conventional Balance Training (CBT)
Number of subjects: 34
Study 33242769 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 43
Study 33242769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 43
Study 33242769 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched healthy subjects)
Number of subjects: 43
Study 36099408 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative respiratory therapy (EG)
Number of subjects: 71
Study 36099408 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study 33813141 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexyn2a bioconjugate vaccine
Number of subjects: 0
Study 32027212 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decompressive craniectomy
Number of subjects: 155
Study 32027212 — intervention group
Group type: COMPARATOR
Intervention: Standard care (intensive medical therapies)
Number of subjects: 155
Study 35766451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional brace
Number of subjects: 15
Study 35766451 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band
Number of subjects: 15
Study 35766451 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional brace
Number of subjects: 15
Study 32869895 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (≥ 80 points)
Number of subjects: 9591
Study 32869895 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk group (50–79 points)
Number of subjects: 9591
Study 32869895 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (30–49 points)
Number of subjects: 9591
Study 35683562 — intervention group
Group type: EXPERIMENTAL
Intervention: Home adaptation (HA)
Number of subjects: 66
Study 35683562 — intervention group
Group type: COMPARATOR
Intervention: Outpatient adaptation (OA)
Number of subjects: 66
Study 32294874 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 123
Study 36378059 — intervention group
Group type: EXPERIMENTAL
Intervention: Liu-zi-jue plus conventional therapy
Number of subjects: 104
Study 36378059 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 104
Study 33415873 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (1% lidocaine 4 mL after acupuncture)
Number of subjects: 60
Study 33415873 — intervention group
Group type: COMPARATOR
Intervention: Simple medication (1% lidocaine 30 mL)
Number of subjects: 60
Study 33902152 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load (80% 1RM)
Number of subjects: 15
Study 33902152 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-load (40% 1RM)
Number of subjects: 15
Study 33902152 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention)
Number of subjects: 15
Study 33524439 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific health warning labels (HWLs)
Number of subjects: 63
Study 33524439 — intervention group
Group type: EXPERIMENTAL
Intervention: General health warning labels (HWLs)
Number of subjects: 63
Study 33524439 — intervention group
Group type: COMPARATOR
Intervention: Non-warning control HWLs
Number of subjects: 63
Study 35822682 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin
Number of subjects: 40
Study 35822682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33934988 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 746
Study 33934988 — intervention group
Group type: COMPARATOR
Intervention: Volatile Anesthetics
Number of subjects: 746
Study 33934988 — intervention group
Group type: COMPARATOR
Intervention: Volatile Anesthetics exposure quantified using area under the end-tidal expired anesthetic agent versus time curves
Number of subjects: 746
Study 33150133 — intervention group
Group type: COMPARATOR
Intervention: nPPCI
Number of subjects: 1266
Study 33150133 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI
Number of subjects: 1266
Study 36106361 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% sodium bicarbonate toothpaste
Number of subjects: 0
Study 36106361 — intervention group
Group type: COMPARATOR
Intervention: Non-sodium bicarbonate (regular) toothpaste
Number of subjects: 0
Study 33047252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 308
Study 33047252 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 308
Study 35236191 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer (D‐D) and fibrinogen (FIB) testing every 8 hours during catheter-directed thrombolysis (CDT)
Number of subjects: 20
Study 35236191 — intervention group
Group type: COMPARATOR
Intervention: Venography and FIB testing every 24 hours during catheter-directed thrombolysis (CDT)
Number of subjects: 20
Study 32895063 — intervention group
Group type: EXPERIMENTAL
Intervention: High smoker identity among dependent smokers
Number of subjects: 391
Study 32895063 — intervention group
Group type: COMPARATOR
Intervention: Low smoker identity among dependent smokers
Number of subjects: 391
Study 32895063 — intervention group
Group type: COMPARATOR
Intervention: Non-dependent smokers
Number of subjects: 391
Study 33807102 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h time-restricted eating (TRE)
Number of subjects: 54
Study 33807102 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary advice (SDA)
Number of subjects: 54
Study 32326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training (SupExT)
Number of subjects: 219
Study 32326133 — intervention group
Group type: COMPARATOR
Intervention: Attentional control (AC)
Number of subjects: 219
Study 32326133 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention (6 months unsupervised)
Number of subjects: 219
Study 34315439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant everolimus plus letrozole for 18 weeks
Number of subjects: 40
Study 34315439 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles
Number of subjects: 40
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-related hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year incidence rate of pre-hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year incidence rate of hypertension
Number of subjects: 9987
Study 32929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hypertension control
Number of subjects: 9987
Study 36098133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 210 mg
Number of subjects: 250
Study 36098133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 700 mg
Number of subjects: 250
Study 36098133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 70 mg
Number of subjects: 250
Study 36098133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 32347763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg subcutaneously weekly or every 2 weeks)
Number of subjects: 2444
Study 32347763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant topical corticosteroids (TCS)
Number of subjects: 2444
Study 32347763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2444
Study 32347763 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS) alone
Number of subjects: 2444
Study 34270825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib consolidation (1.6 mg/m² IV on days 1, 8, 15, 22)
Number of subjects: 340
Study 34270825 — intervention group
Group type: COMPARATOR
Intervention: Observation (no bortezomib consolidation)
Number of subjects: 340
Study 34270825 — intervention group
Group type: EXPERIMENTAL
Intervention: Double ASCT (without bortezomib consolidation)
Number of subjects: 340
Study 35842816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin/praziquantel (0.2 mg/kg)
Number of subjects: 36
Study 35842816 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin/praziquantel (0.4 mg/kg)
Number of subjects: 36
Study 35842816 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 36
Study 33387588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal rich in saturated fatty acids (SFA)
Number of subjects: 16
Study 33387588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal rich in monounsaturated fatty acids (MUFA)
Number of subjects: 16
Study 33387588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal rich in polyunsaturated fatty acids (PUFA)
Number of subjects: 16
Study 33387588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum buffet meal after 3 h postprandial period
Number of subjects: 16
Study 35325108 — intervention group
Group type: EXPERIMENTAL
Intervention: CC‐486 (oral azacitidine) 300 mg daily in a 2 weeks on/2 weeks off schedule
Number of subjects: 0
Study 35325108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35718216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention
Number of subjects: 21
Study 35602344 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education model based on protective motivation theory
Number of subjects: 90
Study 35602344 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing health education measures
Number of subjects: 90
Study 33957695 — intervention group
Group type: COMPARATOR
Intervention: Randomized double-blind placebo-controlled clinical trial
Number of subjects: 0
Study 33957695 — intervention group
Group type: COMPARATOR
Intervention: Open label trials
Number of subjects: 0
Study 33957695 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded trials
Number of subjects: 0
Study 33957695 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for blinding and design
Number of subjects: 0
Study 35760082 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VH) technique targeting an end‐tidal CO2 (ETCO2)<20 mmHg
Number of subjects: 32
Study 35760082 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (AZ)
Number of subjects: 32
Study 35760082 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VH)
Number of subjects: 32
Study 34097069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) along with Pregabalin
Number of subjects: 40
Study 34097069 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 40
Study 34380542 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool
Number of subjects: 1145
Study 34380542 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1145
Study 33531467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental distancing from cigarettes (non-motor retraining)
Number of subjects: 187
Study 33531467 — intervention group
Group type: COMPARATOR
Intervention: Control condition (suppressing or observing the image of a cigarette)
Number of subjects: 187
Study 33990814 — intervention group
Group type: COMPARATOR
Intervention: 0% Brazil nut extract
Number of subjects: 5
Study 33990814 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Brazil nut extract
Number of subjects: 5
Study 33990814 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Brazil nut extract
Number of subjects: 5
Study 33990814 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% Brazil nut extract
Number of subjects: 5
Study 33990814 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Brazil nut extract
Number of subjects: 5
Study 35886690 — intervention group
Group type: EXPERIMENTAL
Intervention: END (endurance-trained group)
Number of subjects: 32
Study 35886690 — intervention group
Group type: EXPERIMENTAL
Intervention: STR (strength-trained group)
Number of subjects: 32
Study 35886690 — intervention group
Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 32
Study 33070419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 80 mg
Number of subjects: 0
Study 33070419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg
Number of subjects: 0
Study 33070419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33326711 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070 7.6 mg/24 h
Number of subjects: 614
Study 33326711 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070 3.8 mg/24 h
Number of subjects: 614
Study 33326711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 35249270 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin add-on insulin therapy
Number of subjects: 50
Study 35249270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33186858 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib for 24 months
Number of subjects: 193
Study 33186858 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VP) every 3 weeks for four cycles
Number of subjects: 193
Study 35973668 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 50 mg daily
Number of subjects: 99
Study 35973668 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 100 mg daily
Number of subjects: 99
Study 35973668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 33472913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 20 mg/m2, days 1-5, combined with gemcitabine (1,000 mg/m2, i.v., days 8 + 15) and cisplatin (70 mg/m2, i.v., day 8)
Number of subjects: 20
Study 33472913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 20
Study 33472913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine combined with gemcitabine and cisplatin
Number of subjects: 20
Study 32873584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear plastic sheet covering the manikin
Number of subjects: 5
Study 32873584 — intervention group
Group type: EXPERIMENTAL
Intervention: Plexiglass intubation box over the manikin
Number of subjects: 5
Study 32873584 — intervention group
Group type: EXPERIMENTAL
Intervention: No barrier
Number of subjects: 5
Study 32873584 — intervention group
Group type: COMPARATOR
Intervention: Control group (assistant)
Number of subjects: 5
Study 35394800 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor (60 mg) twice weekly in 6-week cycles
Number of subjects: 285
Study 35394800 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 285
Study 34097045 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGCR GRS equivalent to a 10‐mg/dL decrease in LDL cholesterol
Number of subjects: 53385
Study 34097045 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGCR GRS
Number of subjects: 53385
Study 32688457 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified scalp retractor
Number of subjects: 32
Study 32688457 — intervention group
Group type: COMPARATOR
Intervention: Traditional scalp retractor
Number of subjects: 32
Study 35078407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively enhanced Tai Ji Quan
Number of subjects: 69
Study 35078407 — intervention group
Group type: COMPARATOR
Intervention: Standard Tai Ji Quan
Number of subjects: 69
Study 35078407 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 69
Study 33770114 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling during pre-discharge period
Number of subjects: 21280
Study 33770114 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling during post-discharge period
Number of subjects: 21280
Study 33770114 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling during both pre- and post-discharge periods
Number of subjects: 21280
Study 33770114 — intervention group
Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 21280
Study 32605578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium quadruple viable tablet
Number of subjects: 300
Study 32605578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard demand creation (SDC)
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand creation plus offer of HIV self-testing (HIVST)
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-centred design (HCD)
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD-informed demand creation approach plus offer of HIVST
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD alone
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: Static (fixed) model
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated (mobile) model
Number of subjects: 15
Study 34275870 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 15
Study 33040003 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Nutrition Project algorithm-based diet
Number of subjects: 0
Study 33040003 — intervention group
Group type: COMPARATOR
Intervention: Low-fat high-dietary fibre diet
Number of subjects: 0
Study 35644973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1sIPV+2bOPV
Number of subjects: 205
Study 35644973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2sIPV+1bOPV
Number of subjects: 205
Study 35644973 — intervention group
Group type: EXPERIMENTAL
Intervention: 3sIPV
Number of subjects: 205
Study 35644973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2sIPV+1bOPV and 3sIPV
Number of subjects: 205
Study 32097223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed first newborn bath (at least 12 hours of age)
Number of subjects: 1463
Study 32097223 — intervention group
Group type: COMPARATOR
Intervention: Routine first newborn bath (within 2 hours of age)
Number of subjects: 1463
Study 34246197 — intervention group
Group type: EXPERIMENTAL
Intervention: αCT1
Number of subjects: 0
Study 34203034 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp-delivered intervention (additional teaching material every two weeks for eight weeks)
Number of subjects: 45
Study 34203034 — intervention group
Group type: COMPARATOR
Intervention: Control group (received printed pamphlet only)
Number of subjects: 45
Study 32970635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 0
Study 32970635 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir prophylaxis
Number of subjects: 0
Study 32385158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 128
Study 32385158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 128
Study 32385158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 35107050 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT02 (40 mg dose)
Number of subjects: 392
Study 35107050 — intervention group
Group type: COMPARATOR
Intervention: EU-reference product (adalimumab) (40 mg dose)
Number of subjects: 392
Study 35107050 — intervention group
Group type: COMPARATOR
Intervention: US-reference product (adalimumab) (40 mg dose)
Number of subjects: 392
Study 35107050 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (AVT02, EU-reference, US-reference)
Number of subjects: 392
Study 33356889 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 33356889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to surgical trauma)
Number of subjects: 0
Study 33555912 — intervention group
Group type: EXPERIMENTAL
Intervention: CanDirect
Number of subjects: 245
Study 33555912 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 245
Study 32576225 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1 antibody)
Number of subjects: 75
Study 32576225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Atezolizumab
Number of subjects: 75
Study 32576225 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Placebo
Number of subjects: 75
Study 33593675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed custom open trays
Number of subjects: 22